Teriflunomide (trade name Aubagio marketed by Sanofi also known as A77 1726) is the active metabolite of leflunomide. Teriflunomide was investigated in the Phase III clinical trial TEMSO as a medication for multiple sclerosis (MS). The study was completed in July 2010. 2-year results were positive.
This page contains content from the copyrighted Wikipedia article "Teriflunomide"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
